Ubrelvy Maximum Dose and Side Effects
The maximum dose of Ubrelvy (ubrogepant) is 200 mg in a 24-hour period, administered as either 50 mg or 100 mg initially, with an optional second dose at least 2 hours later. 11
Dosing Specifications
- Initial dose: 50 mg or 100 mg orally with or without food
- Second dose: May be taken at least 2 hours after the initial dose if needed
- 24-hour maximum: 200 mg total
- Monthly limit: Safety of treating more than 8 migraines in a 30-day period has not been established 11
Dose Modifications Required
Reduce to 50 mg initial dose (avoid second dose within 24 hours) with:
- Moderate CYP3A4 inhibitors
- Severe hepatic impairment (Child-Pugh Class C)
- Severe renal impairment (CrCl 15-29 mL/min)
- BCRP and/or P-gp inhibitors 11
Avoid Ubrelvy entirely with:
- Strong CYP3A4 inhibitors (contraindicated)
- Strong CYP3A4 inducers
- End-stage renal disease (CrCl <15 mL/min) 11
Side Effects
Common Side Effects
The most frequently reported adverse events are generally mild to moderate and transient. Based on the FDA label and clinical trial data, common side effects include:
- Nausea (reported in approximately 6-7% of patients)
- Dizziness
- Somnolence/drowsiness
- General digestive complaints
- Asthenia/fatigue 1
Serious Side Effects and Warnings
Hypersensitivity Reactions (can occur minutes, hours, or days after administration):
- Anaphylaxis
- Dyspnea
- Facial or throat edema
- Rash, urticaria, pruritus
- Action required: Discontinue Ubrelvy immediately if serious hypersensitivity occurs 1
Hypertension (new-onset or worsening):
- Most frequently reported within 7 days of therapy initiation
- May require initiation of antihypertensive treatment
- Some cases required hospitalization
- Action required: Monitor blood pressure; consider discontinuation if hypertension is inadequately controlled or no alternative etiology is found 1
Clinical Context
Important note: The question mentions "rizatriptan" but asks about Ubrelvy. These are different medications. Ubrelvy is ubrogepant (a CGRP antagonist), not rizatriptan (a triptan). The evidence provided about rizatriptan 234567 is not applicable to Ubrelvy dosing or side effects.
According to current guidelines, Ubrelvy is positioned as a treatment option for moderate to severe acute episodic migraine in patients who do not tolerate or have inadequate response to combination therapy of a triptan and an NSAID or acetaminophen 8.
Safety Considerations
- Ubrelvy can be safely coadministered with triptans if needed as rescue medication, with no new safety concerns identified 9
- The drug achieves both central and peripheral exposure, with CSF concentrations sufficient for therapeutic effect 10
- Treatment satisfaction and tolerability profiles support its use in appropriate patient populations